IMI 2
The Innovative Medicines Initiative (IMI) is a large-scale public–private partnership between the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The goal of IMI, particularly in its second phase (IMI2, 2014-2020) is to develop next generation vaccines, medicines and treatments, such as new antibiotics.
Within IMI2 the University of Pisa is partner to 4 projects:
Translational approaches to disease modifying therapy of type 1 diabetes: an innovative approach towards understanding and arresting type 1 diabetes
Assessing risk and progression of prediabetes and type 2 diabetes to enable disease modification
Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory, and Allergic Conditions
Translational approaches to disease modifying therapy of type 1 diabetes - HARVESTing the fruits of INNODIA